MedX Health Corp. Closes $2.8M Series IV Convertible Loan Notes Private Placement

Why It Matters

The financing strengthens MedX’s balance sheet while fueling growth in its teledermatology platform, positioning the company to capture expanding demand for non‑invasive skin‑screening solutions.

Key Takeaways

• Final closing raised $2.8 M CAD (~$2.1 M USD) in Series IV notes.
• Notes carry 6% annual interest, payable quarterly, maturing Dec 31 2028.
• Holders can convert notes to units at $0.10 CAD ($0.074 USD) each.
• Insiders exchanged $2.4 M CAD Series I notes for Series IV notes.
• Agents earned $6,000 CAD and 60,000 warrants as compensation.

Pulse Analysis

MedX Health Corp., a Canadian medical‑technology firm, has built a niche around its SIAscopy® imaging system and DermSecure® telemedicine platform. The company’s technology, cleared by regulators in North America, Europe, and Australia, enables painless, multi‑parameter skin analysis, a capability increasingly sought after by occupational health providers and aesthetic clinics. As telehealth adoption accelerates, firms like MedX are attracting capital to scale distribution and enhance product features, positioning themselves at the forefront of digital dermatology.

The recent private placement of Series IV Convertible Loan Notes closed at $2.8 M CAD (about $2.1 M USD), adding 6% interest‑bearing debt that matures at the end of 2028. Investors can convert the notes into units priced at $0.10 CAD per unit, each comprising a common share and half a warrant, with full warrants exercisable at $0.125 CAD ($0.092 USD). By swapping $2.4 M CAD of existing Series I notes, the company reduces legacy debt while preserving cash for strategic initiatives. Agent commissions of $6,000 CAD and 60,000 non‑transferable warrants align distribution incentives without diluting existing shareholders.

The infusion supports MedX’s roadmap to expand SIAscopy® into occupational health markets and broaden its teledermatology services. With skin‑cancer screening becoming a preventive priority for employers, the platform’s rapid, non‑invasive diagnostics offer a compelling value proposition. Moreover, the financing underscores investor confidence in MedX’s growth trajectory, suggesting that capital markets remain receptive to niche health‑tech innovators that combine regulatory clearance with scalable digital platforms.

Deal Summary

MedX Health Corp. announced the final closing of its non‑brokered private placement of Series IV Convertible Loan Notes, issuing a total of $2.8 million in notes. The placement includes $2.4 million converted from Series I notes, $300,000 from new subscriptions, and an additional $100,000 in further subscriptions. Proceeds will be used to replace the Series I notes and fund development of the company's SIAscopy® telemedicine platform.